Clinical trials: Superficial Vein Thrombosis
Venous Malformation, Low Flow, Venous Malformations
Acetylsalicylic Acid Versus Placebo as an add-on Treatment to Local Non-steroidal Anti-inflammatory Drug for the Management of Thrombotic Episodes in Superficial Venous Malformations in Children Aged 6 to 17 Years.
Superficial venous malformations (SVMs) are rare congenital anomalies that present as bluish masses. These masses may be focal, with limited skin involvement, or segmental, with more extensive involvement.
- Trial name
- ASPIRIN (NCT07663825)
- Testing
- AAS at anti-inflammatory doses from 3 days to 14 days., Application of Diclofenac gel 1% twice a day
- Where
- 6 sites in France
- Volunteers
- 34 people
- Sponsor
- University Hospital, Tours
Superficial Vein Thrombosis, D-dimer
Superficial Vein Thrombosis Testing in the Emergency Department
Superficial vein thrombosis (SVT) occurs when blood in a vein directly under the skin clots. SVT causes vein tenderness, pain, and skin discolouration. Over time, the vein hardens into a firm, nontender, easily palpable lump.
- Trial name
- SVTest (NCT07671300)
- Testing
- D-dimer
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- Dr. Kerstin de Wit
Superficial Vein Thrombosis, Cancer
Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous
Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT.
- Conditions
- Superficial Vein Thrombosis, Cancer, Venous Thrombosis
- Trial name
- SUPERCAT (NCT07210671)
- Where
- France
- Volunteers
- 1,576 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Chronic Venous Thrombosis, Venous Thrombosis Upper Extremity
Surfacer System to Facilitate Access in Venous Occlusions
Prospective, single-arm, multicentre, international Registry of the Surfacer System for the treatment of patients with limited or diminishing upper body venous access or pathology impeding standard access methods.The purpose of…
- Conditions
- Chronic Venous Thrombosis, Venous Thrombosis Upper Extremity, Venous Thrombosis Upper Extremity Superficial Veins
- Trial name
- SAVE (NCT02875899)
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Merit Medical Systems, Inc.
Deep Vein Thrombosis, Superficial Thrombophlebitis
DOACT Algorithm Versus AI-Based Decision Models in Oral Anticoagulant Therapy for Vascular Patients
Study using a decision algorithm for the application of an oral anticoagulant calculator in vascular diseases, aimed at validating a clinical decision-support tool for conditions such as deep vein thrombosis, superficial…
- Conditions
- Deep Vein Thrombosis, Superficial Thrombophlebitis, Pulmonary Thromboembolisms, Clinical Decision Support Systems
- Trial name
- DOACT (NCT07290608)
- Testing
- DOACT algorithm, No algorithm, LLM-based tools
- Where
- Brazil
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- ITALO EUGENIO SOUZA GADELHA DE ABREU
Thrombosis, Venous
ARIXTRA® Adherence in SVT Patients.
Fondaparinux is an anticoagulant used in the prevention and treatment of thromboembolic disease. It has recently been approved in the European Union (EU) for the treatment of patients with isolated superficial vein thrombosis…
- Trial name
- NCT01691495
- Testing
- Fondaparinux
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Thrombosis, Venous
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
To evaluate fondaparinux 2.5mg subcutaneously once daily for 45 days in the treatment of acute (recent) superficial thrombophlebitis.
- Trial name
- NCT00443053
- Where
- 227 sites in Bulgaria, Czechia and 15 more
- Volunteers
- 3,002 people
- Sponsor
- GlaxoSmithKline
Superficial Vein Thrombosis
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban versus fondaparinux in the treatment of superficial vein thrombosis (SVT).
- Trial name
- NCT01499953
- Testing
- Rivaroxaban, Fondaparinux
- Where
- 23 sites in Germany
- Volunteers
- 472 people
- Sponsor
- GWT-TUD GmbH
Venous Thrombosis or Pulmonary Embolism
What Treatment for Patients With Phlebitis or Pulmonary Embolism ?
The objective of the "anticoagchoice" study is to analyze the preferences of people suffering from phlebitis, in terms of anticoagulant, to improve adherence to these treatments, to adapt the medical prescriptions.
- Trial name
- AntiCoagChoice (NCT03889457)
- Testing
- anticoagulation choice
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Rennes University Hospital
Varicose Veins, Superficial Venous Thrombosis
Comparison of Daytime Surgery in Varicose Veins Patients With and Without Superficial Venous Thrombosis
Varicose veins of lower extremities are the most common disease in vascular surgery, and daytime surgery has gradually become the mainstream of varicose veins of lower extremities.
- Conditions
- Varicose Veins, Superficial Venous Thrombosis, Day Surgery
- Trial name
- NCT05380895
- Where
- China
- Volunteers
- 699 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Varicose Veins
Evaluation of Endovenous Sclerotherapy for Treatment of Varicose Veins
The overall objective will be to evaluate clinical predictors of outcomes in patients who undergo endovenous sclerotherapy for the treatment of varicose veins.
- Trial name
- NCT00954980
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Venous Thromboembolism, Varicose Veins
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin.
- Trial name
- THRIVE (NCT05735639)
- Testing
- Dalteparin Sodium, Tinzaparin Sodium, Enoxaparin Sodium
- Where
- United Kingdom
- Volunteers
- 3,175 people
- Sponsor
- Imperial College London
Superficial Thrombophlebitis
Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis
The aim of the study is to establish whether treatment of superficial vein thrombosis (SVT) with low-molecular-weight heparin in preventive or therapeutic doses prevents disease progression and thromboembolic events (deep vein…
- Trial name
- REVETR (NCT01245998)
- Testing
- Dalteparin
- Where
- Slovenia
- Volunteers
- 68 people
- Sponsor
- University Medical Centre Ljubljana
Thrombophlebitis, Phlebitis
Efficacy and Tolerability of Hirudoid Cream in Prophylaxis and Treatment Infusion Phlebitis
Patients receiving nutritional emulsion for at least 3 days will be treated with Hirudoid cream or placebo cream to prevent and treat phlebitis caused by the infusion.
- Trial name
- NCT01943006
- Testing
- Hirudoid cream 0.3 % Mucopolysaccharide polysulfate
- Where
- 4 sites in Thailand
- Volunteers
- 144 people
- Sponsor
- Medinova AG
Thromboembolic Complications
Thrombelastography Based Dosing of Enoxaparin
The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox®) is given to patients who are at a higher risk of developing clots in their legs or lungs.
- Trial name
- NCT00990236
- Testing
- Enoxaparin dose adjusted Lovenox based on TEG, Enoxaparin 30 mg BID
- Where
- 3 sites in United States
- Volunteers
- 185 people
- Sponsor
- Oregon Health and Science University
Superficial Venous Thrombosis of Leg, Secondary Prevention
Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis
The objective of the study is to demonstrate the superiority of the mesoglycan (Prisma®), compared to placebo, in reducing the incidence of thromboembolic complications (relapse / extension of superficial venous thrombosis (SVT)…
- Trial name
- NCT03428711
- Testing
- Mesoglycan Oral Tablet
- Where
- Italy
- Volunteers
- 560 people
- Sponsor
- Quovadis Associazione
Symptomatic Superficial Vein Thrombosis
Rivaroxaban Anticoagulation for Superficial Vein Thrombosis
This is a Phase III, randomized, placebo controlled, blinded, parallel two arm, multicentre trial that will compare rivaroxaban 10mg daily with placebo in patients with symptomatic leg Superficial Vein Thrombosis (> or = 5cm)…
- Trial name
- RASET (NCT02123524)
- Testing
- Rivaroxaban
- Where
- 11 sites in Canada
- Volunteers
- 85 people
- Sponsor
- McMaster University
Superficial Vein Thrombosis
Incidence of Superficial Vein Thrombosis
To date, the investigators still do not know the annual incidence of Superficial Vein Thrombosis in the legs, although the investigators do know that this pathology is frequent and the investigators can assume its incidence is…
- Trial name
- STEPH (NCT01501175)
- Testing
- consultation with a vascular physician
- Where
- 7 sites in France
- Volunteers
- 848 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Superficial Vein Thrombosis, Endovenous Laser Ablation
Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein
Рrospective single-centre randomized open-label study for comparison three modes of treatment for thrombosis of varicose great saphena vein - standard medical with fondaparinux sodium for 45 days, endovenous laser ablation close…
- Trial name
- NCT05001776
- Testing
- Endovenous laser ablation, Fondaparinux Sodium
- Where
- Russia
- Volunteers
- 105 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Catheter Associated Infection
Superficial Vein Thrombosis of the Upper Limb in Bacteremia Associated With PICCline and Midline Catheters: Frequency and Clinical Consequences
The use of long-term peripheral venous catheters inserted in the upper limb (PICC lines and Midlines) has increased markedly over recent years.
- Trial name
- THROMBI-CATH (NCT07388381)
- Testing
- Follow-up for catheter-related bacteremia
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Nice